Literature DB >> 25869403

Primum non nocere and challenging conventional treatment.

Adam M Deane1, Gordon H Guyatt.   

Abstract

Mesh:

Substances:

Year:  2015        PMID: 25869403     DOI: 10.1007/s00134-015-3785-2

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  15 in total

Review 1.  Stress ulceration: prevalence, pathology and association with adverse outcomes.

Authors:  Mark P Plummer; Annika Reintam Blaser; Adam M Deane
Journal:  Crit Care       Date:  2014-03-18       Impact factor: 9.097

2.  Administration of proton pump inhibitors in critically ill medical patients is associated with increased risk of developing Clostridium difficile-associated diarrhea.

Authors:  Lukas Buendgens; Jan Bruensing; Michael Matthes; Hanna Dückers; Tom Luedde; Christian Trautwein; Frank Tacke; Alexander Koch
Journal:  J Crit Care       Date:  2014-03-07       Impact factor: 3.425

3.  Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group.

Authors:  D J Cook; H D Fuller; G H Guyatt; J C Marshall; D Leasa; R Hall; T L Winton; F Rutledge; T J Todd; P Roy
Journal:  N Engl J Med       Date:  1994-02-10       Impact factor: 91.245

4.  Prevalence and outcome of gastrointestinal bleeding and use of acid suppressants in acutely ill adult intensive care patients.

Authors:  Mette Krag; Anders Perner; Jørn Wetterslev; Matt P Wise; Mark Borthwick; Stepani Bendel; Colin McArthur; Deborah Cook; Niklas Nielsen; Paolo Pelosi; Frederik Keus; Anne Berit Guttormsen; Alma D Moller; Morten Hylander Møller
Journal:  Intensive Care Med       Date:  2015-04-10       Impact factor: 17.440

5.  Opinions and practice of stress ulcer prophylaxis in Australian and New Zealand intensive care units.

Authors:  Glenn M Eastwood; Ed Litton; Rinaldo Bellomo; Michael J Bailey; Mario Festa; Richard W Beasley; Paul J Young
Journal:  Crit Care Resusc       Date:  2014-09       Impact factor: 2.159

6.  Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012.

Authors:  R P Dellinger; Mitchell M Levy; Andrew Rhodes; Djillali Annane; Herwig Gerlach; Steven M Opal; Jonathan E Sevransky; Charles L Sprung; Ivor S Douglas; Roman Jaeschke; Tiffany M Osborn; Mark E Nunnally; Sean R Townsend; Konrad Reinhart; Ruth M Kleinpell; Derek C Angus; Clifford S Deutschman; Flavia R Machado; Gordon D Rubenfeld; Steven Webb; Richard J Beale; Jean-Louis Vincent; Rui Moreno
Journal:  Intensive Care Med       Date:  2013-01-30       Impact factor: 17.440

7.  Histamine-2 receptor antagonists vs proton pump inhibitors on gastrointestinal tract hemorrhage and infectious complications in the intensive care unit.

Authors:  Robert MacLaren; Paul M Reynolds; Richard R Allen
Journal:  JAMA Intern Med       Date:  2014-04       Impact factor: 21.873

Review 8.  Burden of Clostridium difficile on the healthcare system.

Authors:  Erik R Dubberke; Margaret A Olsen
Journal:  Clin Infect Dis       Date:  2012-08       Impact factor: 9.079

9.  Proton pump inhibitors increase the risk for hospital-acquired Clostridium difficile infection in critically ill patients.

Authors:  Jeffrey F Barletta; David A Sclar
Journal:  Crit Care       Date:  2014-12-24       Impact factor: 9.097

Review 10.  Ventilator-associated pneumonia: present understanding and ongoing debates.

Authors:  Girish B Nair; Michael S Niederman
Journal:  Intensive Care Med       Date:  2014-11-27       Impact factor: 17.440

View more
  2 in total

1.  Trials on stress ulcer prophylaxis: finding the balance between benefit and harm.

Authors:  Mette Krag; Anders Perner; Jørn Wetterslev; Matt P Wise; Morten Hylander Møller
Journal:  Intensive Care Med       Date:  2015-06-03       Impact factor: 17.440

2.  Trials on stress ulcer prophylaxis: finding the balance between benefit and harm. Response to Krag et al.

Authors:  Adam M Deane; Gordon H Guyatt
Journal:  Intensive Care Med       Date:  2015-06-19       Impact factor: 17.440

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.